NCT06475586View on ClinicalTrials.gov

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

June 10, 2024

Conditions
Psoriasis VulgarisDiabetes Type 2
Interventions
DRUG

Semaglutide

0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks

Trial Locations (1)

78000

University of Banja Luka, Faculty of Medicine, Banja Luka

All Listed Sponsors
lead

University of Banja Luka

OTHER

NCT06475586 - Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter